Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Alglucerase is a modified human enzyme used as the first placenta-derived enzyme replacement therapy for Type 1 Gaucher's disease. Approved by the FDA in 1991, it has since been largely replaced by recombinant alternatives like imiglucerase (Cerezyme), velaglucerase alfa (VPRIV), and taliglucerase alfa (Elelyso).
Alglucerase is a modified human enzyme used as the first placenta-derived enzyme replacement therapy for Type 1 Gaucher's disease. Approved by the FDA in 1991, it has since been largely replaced by recombinant alternatives like imiglucerase (Cerezyme), velaglucerase alfa (VPRIV), and taliglucerase alfa (Elelyso).